Talphera (FRA:R5XA) Cyclically Adjusted PS Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R5XA Talphera Inc FRA:R5XA
32 GF Score
Price €1.02
! 4 Warning Signs
View Full Analysis

What is Talphera Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Talphera  (FRA:R5XA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Talphera Cyclically Adjusted PS Ratio Related Terms


Talphera Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Talphera's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Talphera Cyclically Adjusted PS Ratio Chart

Talphera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.20 0.00 0.00

Talphera Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:R5XA vs CPHI, ZYBT, INCR: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talphera Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Talphera's Cyclically Adjusted PS Ratio falls into.


FRA:R5XA
32GF Score
Talphera Inc FRA:R5XA
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Talphera Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Talphera's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Talphera's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/333.9520*333.9520
=0.000

Current CPI (Jun. 2026) = 333.9520.

Talphera Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.323 241.428 1.830
201612 2.691 241.432 3.722
201703 1.282 243.801 1.756
201706 1.043 244.955 1.422
201709 0.538 246.819 0.728
201712 0.248 246.524 0.336
201803 0.109 249.554 0.146
201806 0.270 251.989 0.358
201809 0.108 252.439 0.143
201812 0.152 251.233 0.202
201903 0.060 254.202 0.079
201906 0.211 256.143 0.275
201909 0.139 256.759 0.181
201912 0.108 256.974 0.140
202003 0.087 258.115 0.113
202006 0.644 257.797 0.834
202009 0.264 260.280 0.339
202012 0.131 260.474 0.168
202103 0.076 264.877 0.096
202106 0.062 271.696 0.076
202109 0.266 274.310 0.324
202112 0.000 278.802 0.000
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.021 305.109 0.023
202309 0.007 307.789 0.008
202312 0.014 306.746 0.015
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.001 319.799 0.001
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.000 324.054 0.000
202603 0.000 330.213 0.000
202606 0.000 333.952 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Talphera Business Description

Other Exchanges TLPH:USA
Address 1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
32GF Score

Get the complete analysis for FRA:R5XA

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.02
Price